Journal of Advances in Biology & Biotechnology

24(12): 30-39, 2021; Article no.JABB.82932
ISSN: 2394-1081

Synthesis, Characterization and Biological Evaluation of Chalcones and Its Derivatives for Antibacterial and Anti Inflammatory Activity

Geeta Lodhi [a*] and Amit Nayak [a]

[a] R. K. D. F. College of Pharmacy, SRK University Bhopal, Madhya Pradesh, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JABB/2021/v24i1230256

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/82932

Original Research Article

Received 20 October 2021
Accepted 25 December 2021
Published 27 December 2021

ABSTRACT

Chemistry or Medicinal chemistry is a discipline at the Interchange ofchemistry and pharmacology engaged with designing, methodize andcreating drug chalcones is a conventional term given tointensifies bearing the (E)- 1,3-diphenylprop-2-en-1-one, which can befunctionlized in the propane chain by the presence of olefinic, keto as well ashydroxyl group.Chalcones are a significant class of regular items and are considered as the forerunners of flavonoids and isoflavonoids. Synthetically, is (E)-1,3-diphenylprop-2-en-1-one in which two aromatic ring rings are joined by a three carbon bond having a carbonyl moiety and and α, β unsaturation. The compounds with the backbone of chalcones have been accounted for to have different pharmacological activities for example, antimicrobial, anti- inflammatory, analgesic, anti-platelet, anti-ulcerative, antimalarial, anticancer, antiviral, anti-leishmanial, antioxidant, antitubercular, anti-hyperglycemic, immunomodulatory, inhibition of chemical mediators release, inhibition of leukotriene B4, inhibition of tyrosinase and inhibition of aldose reductase activities. This paper mainly focuses on chalcones synthesized by Claisen Schmidt condensation which involves the condensation between an aromatic aldehyde or ketone with an aliphatic ketone or aldehyde catalysed by the presence of dilute alkali or acid to form alpha beta unsaturated compound. through reviewing different biological significance of chalcones andtheir derivatives have been reported along with their antibacterial movement against, Bacillus pumilis, Bacillus subtilis (gram-positive) and Escherichia coli, Proteus vulgaris (gram-negative). The antiinflammatory action of the sixteen chalcones has been assessed byutilizing carrageenan-actuated rodent paw oedema strategy.

**Corresponding author: E-mail: geetalodhi26@gmail.com;*

Keywords: Chalcone; aldol condensation; claisen schmidt condensation; pharmacological-biological activity.

1. INTRODUCTION

Chalcones are a significant class of natural products having a place with the flavonoid family. They are considered as the precursors of flavonoids and. They are considered as the precursors of flavonoids and isoflavonoid. Chalcone (and related compounds “chalconoids”) is an aromatic ketone that forms the central core for a variety of important biological compounds, which are known collectively as chalcones. They are also the precursors of number of biologically important heterocyclic compounds. Chalcones have been used as intermediates for the preparation of compounds having therapeutic value. They are widely distributed in fruits, vegetables, tea, spices, soy foods and other plant products. Chemically, chalcones are (E)-1,3-diphenylprop-2-en-1-one, in which two aromatic rings or subbed substituted rings are combined by a three carbon particle a,ß-unsaturated carbonyl framework. Pharmacological properties of chalcones are because of the presence of both a,ß-unsaturation anda aromatic ring. Chalcones considered as antecedents of flavonoids andisoflavonoids are plentiful in plants [1-3].

They have the following general structure and formula:



Structure of Chalcones (C15H12O)

2. MATERIALS AND METHODS

The following methods for synthesizing chalcones and Chalcones derivatives. All the synthetic compounds were acquired from Sigma-Aldrich, Spectrochem and High Media.. Melting point is determined by utilizing an open capillary and are uncorrected.TLC were performed on silica plates with observation under uv or iodine chamber . Infrared Infrared spectra were recorded on a FT-IR Shimadzu DZU 8400S spectrophotometer in KBr circles and Elemental examination were done on a Perkin-Elmer 2400C, H, N analyzer and values were viewed to be within satisfactory limits reaches of the determined qualities. The 1H-NMR spectra of the methodize mixtures in CDCl3/DMSO were recorded at 400 MHz by Bruker Advance II 400 NMR spectrometer. Chemical shift esteems are given in scale utilizing tetramethylsilane (TMS) as an inside norm. Huge 1H-NMR information are written all together: number of protons, assortment (b, wide; s, singlet; d, doublet; t, trio; m, multiplet), coupling constants in Hertz, task. The fab mass spectra (at room temperature) were recorded on tof MS-ES Mass spectrometer.

2.1 Synthesis of Chalcones

Chalcones are Synthesized by Claisen-Schmidt condensation [4,5] of aldehyde and ketone by base catalyzed or corrosive catalyzed followed by followed by dehydration to yield chalcones.



2.1.1 Mechanism of reaction for synthesis of chalcone derivatives (1a-1p)



The synthesis of the planned mixtures 1a-1h, 2a-2h, 3a-3h (i) Me2CO, RT 6 hr (ii) subbed benzaldehyde, methanolic NaOH, blended at room temperature, 24 hr (iii) n-butanol, reflux (iv) thiosemicarbazide, EtOH, ACOH, reflux.



The Synthesis of the planned mixtures 1i-1p, 2i-2p, 3i-3p (i) CHCl3, rt, 3-6 hrs (ii) subbed benzaldehyde, methanolic NaOH, blended at room temperature, 24 hr (iii) n-butanol, reflux (iv) thiosemicarbazide, EtOH, ACOH, reflux.

2.1.2 Synthesis 3-N-(N'-p-chlorophenylurenyl)acetophenone

Synthesis of methyl ketone subordinate was completed by making m-amino acetophenone respond with the p-chlorophenyl isocyanate. A combination of the m-aminoacetophenone (2.7 g, 20mmol) and p-chlorophenyl isocyanate (3 g, 20 mmol) dissolved in dry CH3)2CO (100 mL). The blend was mixed for 6-7 hr at room temperature, separated, and the crude compound urenylacetophenone was recrystallized utilizing ethanol [6].

2.1.3 Synthesis for of 3-N-(N'-p-chlorophenylurenyl)acetophenone

Yield 3.3 g, 58%, White solid; mp 272-274^{o}C; IR(KBr) ν_{max} /cm^{-1} 3372 (N-H), 3056 (ArC-H), 2962 2872 (C-H), 1711 (COCH3), 1645 (C=O), 1614, 1534, 1461 (Ar C=C), 1515, 1290, 1185 (ArC-N), 1147 (Ar-Cl) 756, 687 (Ar); ^{1}H-NMR (DMSO-d6, 400 MHz): δ_H 9.12 (br s, 1H, NH), 8.91 (br s, 1H, NH); 8.18 (1H, s, H-2), 7.78 (1H, d, J 5.9, H-6), 7.53 (3H, m, H-4, 2', 6'), 7.30 (1H, t, J 6.30, H-5), 7.21 (2H, d, J 6.65, H-3', 5'), 2.53 (s, 3H, 3-COCH3).



Scheme for synthesis of 3-N-(N'-p-chlorophenylurenyl) acetophenone

2.1.4 Synthesis of 3'-N [(2'', 5''-dichlorophenyl) sulfonyl-amide] acetophenone

The intermediate compound 3'-N[(2'',5''-dichlorophenyl) sulfonyl-amide] acetophenone was synthesized adopting the procedure described by Leon et al. [7] with some modifications.



2.1.5 Scheme for synthesis of 3'-N[(2'',5''-dichlorophenyl) sulfonyl-amide] acetophenone

A combination of 3-aminoacetophenone (2.7 g, 20 mmol) and 2, 5-dichloro-benzene sulfonyl chloride (4.9 g, 20 mmol) in 5 mL of chloroform was blended at room temperature (rt) for 3-6 hr. The subsequent accelerate was washed with CH3)2CO, sifted, and the unrefined material acquired was recrystallized in acetonitrile to give pure compound 3'-N[(2'',5''-dichlorophenyl) sulfonyl-amide] acetophenone.

Yield 3.6 g, 52%, Brown crystals; mp 230–232 °C; IR 3216 (N-H); 1667 (C=O); 1715 (COCH3), 1337, 1270 (SO_2), 1142 (Ar-Cl), 3060 (Ar-H), 2967 (C-H), 1584, 1461, 1357, 1297, 1273, 1166, 993, 852, 819, 795, 720 (Ar); ^{1}H-NMR: δ_H 11.38 (s, 1H, NH), 7.94 (1H, s, H-6´´), 7.70 (1H, d, J 8.44, H-3´´), 7.25-7.44 (3H, m, H-2´, 5´, 6'), 7.71 (d, 1H, J 6.42, H-4´´), 6.94 (1H, d, J 8.91, H4'), 2.51 (s, 3H, CH_3CO).

2.1.6 General procedure for the synthesis of chalcone derivatives (1a-1p)

To a solution of substituted acetophenone (16 mmol) in 10 mL of methanol on an ice bath, newly prepared 2 N methanolic NaOH arrangement (60 mL) was added and blended for 10 min. To this, fitting aldehyde (16 mmol) was added and blended at room temperature for12-24 hr. The response combination was cooled on an ice bath, neutralized with diluted HCl and the precipitate was washed multiple times with 50 mL pure water to give the crude item. The item was recrystallized from methanol or ethanol/water.

The purity of the product was checked by TLC using ethylacetate and hexane (4:6) as mobile phase and iodine vapors as detecting agent.

[(E)-1-(4”-chlorophenyl)-3-(3-(3’-(3-hydroxyphenyl)acryloyl)phenyl)urea (1a) (E)-1-(4”-chlorophenyl)-3-(3-(3’-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)urea (1b) Synthesis of (E)-1-(4’’-chlorophenyl)-3-(3-(3’-(2,4-dimethoxyphenyl)acryloyl) phenyl)urea (1c) Synthesis of (E)-1-(4’’-chlorophenyl)-3-(3-(3’-(3,4-dimethoxyphenyl)acryloyl) phenyl)urea (1d) Synthesis of (E)-1-(3-(3-(5-chloro-2-methoxyphenyl)acryloyl)phenyl)-3-(4-chloro-phenyl)urea (1e) Synthesis of (E)-1-(4”-chlorophenyl)-3-(3’-(3-(2,5-dichlorophenyl)acryloyl) phenyl)urea (1f) Synthesis of (E)-1-(4”-chlorophenyl)-3-(3’-(3-(3,4,5-trimethoxyphenyl) acryloyl) phenyl)urea (1g) Synthesis of (E)-1-(4”-chlorophenyl)-3-(3’-(3-(pyridin-3-yl)acryloyl) phenyl) urea (1h) Synthesis of (E)-2”,5”-dichloro-N-(3’-(3-(3-methoxyphenyl)acryloyl)phenyl)benzene sulfonamide (1i) Synthesis of (E)-2”,5”-dichloro-N-(3’-(3-(3-hydroxy,4-methoxyphenyl)acryloyl)phenyl) benzenesulfonamide (1j) Synthesis of (E)-2”,5”-dichloro-N-(3’-(3-(2,4-dimethoxyphenyl)acryloyl)phenyl) benzene sulfonamide (1k) Synthesis of (E)-2”,5”-dichloro-N-(3’-(3-(3,4-dimethoxyphenyl)acryloyl) phenyl) benzene sulfonamide (1l) Synthesis of (E)-2”,5”-dichloro-N-(3’-(3-(5-chloro-2-methoxyphenyl)acryloyl)phenyl) benzenesulfonamide (1m) Synthesis of (E)-2”,5”-dichloro-N-(3’-(3-(2,5-dichlorophenyl)acryloyl)phe nyl) benzenesulfonamide(1n) Synthesis of (E)-2”,5”-dichloro-N-(3’-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenyl)benzene sulfonamide (1o) Synthesis of (E)-2”,5”-dichloro-N-(3’-(3-(pyridin-3-yl)acryloyl)phenyl) benzene sulfonamide (1p)**]**

2.1.7 General method for synthesis of 1, 3, 5-trisubstituted pyrazolines (2a-2p)

1,3,5-trisubstituted pyrazolines (**2a-2p**) were combined by the plan portrayed in Ozdemir et al., [8]. In this strategy, chalcone and nicotinic corrosive hydrazide were refluxed in n-butanol to combine the ideal item [9]. Factors, for example, the design and position of the substituents have significantly affected the rate of the response. The generally most part acknowledged translation of this response, includes the underlying development of an aryl hydrazone with ensuing nucleophilic assault of nitrogen upon the carbon-carbon double bond at position. Consequently the electropositive idea of carbon might control the general pace of the response. The electropositive nature of carbon is controlled by the aromatic ring directly connected to it.

Halogens being electron withdrawing in nature significantly increase the positive character of carbon lead to faster reaction while electron donating alkyl and alkoxy groups contributed for slower reaction.



2.1.8 Scheme and mechanism of reaction for synthesis of compounds (2a-2p)

T o the arrangement of the proper chalcone 1a-1p (4 mmol) in 10 mL of n-butanol, (0.55 g, 4 mmol) of nicotinic corrosive hydrazide was added and the response blend was refluxed for 8-10 hr. The overabundance of dissolvable was taken out under decreased strain and the response blend was cooled on an ice shower. The items encouraged out at low temperature were washed multiple times with 50 mL refined water, reconstituted in least measure of methanol and dried under decreased strain. This item was additionally cleaned by crystallization from the ethanol-DMF blend (1:1). Purity of the items was checked by Attention utilizing combination of CH3)2CO and oil ether (40:60 V/V) as mobile phase.

[a-(4”-chlorophenyl)-c-(3-(5''-(3'-hydroxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)urea (2a)
a-(4”-chlorophenyl)-c-(3-(5''-(4’-hydroxy,3'-methoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3- yl)phenyl)urea (2b)
a-(4”-chlorophenyl)-c-(3-(5-(2',4'-dimethoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3- yl)phenyl)urea (2c)
a-(4”-chlorophenyl)-c-(3-(5-(2',4'-dimethoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3- yl)phenyl)urea (2d)
a-(4”-chlorophenyl)-c-(3-(5-(3',4'-dimethoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3- yl)phenyl)urea (2e)
a-(4”-chlorophenyl)-c-(3-(5-(2',5'-dichloroyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3- yl)phenyl)urea (2f)
a-(4”-chlorophenyl)-c-(3-(5-(3',4’,5’-trimethoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3- yl)phenyl)urea (2g)
a-(4”-chlorophenyl)-c-(3-(5-(pyridine-3’-yl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)urea (2h) 2”,5”-dichloro-N-(3-(5-(3'-hydroxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3- yl)phenyl)benzenesulphonamide (2i)
2”,5”-dichloro-N-(3-(5-(4’-hydroxy,3'-methoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3- yl)phenyl)benzenesulphonamide (2j)
2”,5”-dichloro-N-(3-(5-(2',4'-dimethoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)benzenesulphonamide (2k)
2”,5”-dichloro-N-(3-(5-(3',4'-dimethoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)benzenesulphonamide (2l)
2”,5”-dichloro-N-(3-(5-(5’-chloro,2'methoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)benzenesulphonamide (2m)
2”,5”-dichloro-N-(3-(5-(2’,5’-dichlorophenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)benzenesulphonamide (2n)
2”,5”-dichloro-N-(3-(5-(3',4’,5’-trimethoxyphenyl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)benzenesulphonamide (2o)
2”,5”-dichloro-N-(3-(5-(pyridine-3’-yl)-1-nicotinoyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl)benzenesulphonamide (2p)**]**

2.1.9 General procedure for synthesis of thiosemicarbazide derivatives (3a-p)

A mixture of chalcones (3a–3p) (0.5 mmol) and thiosemicarbazide (0.5 mmol) in hot ethanol (50 mL) had a few drops of concentrated hydrochloric acid added. The reaction mixture was stirred atreflux temperature for 2–6 hr, and monitored by TLC using hexane: ethyl acetate (8:2) as the eluent. Afterwards, the precipitate was filtered off and the crude product purified by recrystallization from ethanol, resulting in the target compounds (3a–3p).

[(Z)-2-((E)-1-(3-(3-(4-chlorophenyl)ureido)phenyl)-3-(3hydroxyphenyl)allylidene)hydrazine carbothioamide (3a)
(Z)-2-((E)-1-(3-(3-(4-chlorophenyl)ureido)phenyl)-3-(4-hydroxy-3-methoxyphenyl) allylidene)hydrazine carbothioamide (3b)
(Z)-2-((E)-1-(3-(3-(4-chlorophenyl)ureido)phenyl)-3-(2,4-dimethoxyphenyl)allylidene) hydrazinecarbothioamide (3c)
(Z)-2-((E)-1-(3-(3-(4-chlorophenyl)ureido)phenyl)-3-(3,4-dimethoxyphenyl)allylidene) hydrazinecarbothioamide (3d)
(Z)-2-((E)-3-(5-chloro-2-methoxyphenyl)-1-(3-(3-(4-chlorophenyl)ureido)phenyl) allylidene)hydrazinecarbothioamide (3e)
(Z)-2-((E)-1-(3-(3-(4-chlorophenyl)ureido)phenyl)-3-(2,5-dichlorophenyl)allylidene) hydrazinecarbothioamide (3f)
(Z)-2-((E)-1-(3-(3-(4-chlorophenyl)ureido)phenyl)-3-(3,4,5-trimethoxyphenyl) allylidene)hydrazinecarbothioamide (3g)
(Z)-2-((E)-1-(3-(3-(4-chlorophenyl)ureido)phenyl)-3-(pyridin-3-yl)allylidene)hydrazine carbothioamide (3h)
(Z)-2-((E)-1-(3-(2,5-dichlorophenylsulfonamido)phenyl)-3-(3-hydroxyphenyl) allylidene)hydrazinecarbothioamide (3i)
(Z)-2-((E)-1-(3-(2,5-dichlorophenylsulfonamido)phenyl)-3-(4-hydroxy-

3methoxy phenyl) allylidene)hydrazinecarbothioamide (3j)
(Z)-2-((E)-1-(3-(2,5-dichlorophenylsulfonamido)phenyl)-3-(2,4-dimethoxyphenyl) allylidene)hydrazinecarbothioamide (3k)
(Z)-2-((E)-1-(3-(2,5-dichlorophenylsulfonamido)phenyl)-3-(2,4-dimethoxyphenyl) allylidene)hydrazinecarbothioamide (3l)
(Z)-2-((E)-3-(5-chloro-2-methoxyphenyl)-1-(3-(2,5-dichlorophenylsulfonamido)phenyl)allylidene)hydrazinecarbothioamide (3m)
(Z)-2-((E)-3-(2,5-dichlorophenyl)-1-(3-(2,5-dichlorophenylsulfonamido)phenyl)allylidene) Hydrazine carbothioamide (3n)
(Z)-2-((E)-1-(3-(2,5-dichlorophenylsulfonamido)phenyl)-3-(3,4,5-trimethoxyphenyl) allylidene)hydrazinecarbothioamide (3o)
(Z)-2-((E)-1-(3-(2,5-dichlorophenylsulfonamido)phenyl)-3-(pyridin-3-yl)allylidene) hydrazine carbothioamide (3p)**]**

3. PHARMACOLOGICAL EVOLUTIONS

Antibacterial activity: All the synthesized mixtures (1a-1p, 2a-2p, 3a-3p) have been assessed for their antibacterial movement against, Bacillus pumilis, Bacillus subtilis (gram-positive) and Escherichia coli, Proteus vulgaris (gram-negative)The results of this evaluation have been viewed by taking chloramphenicol (1000 g/mL), a broad spectrum antibiotic as the standard. The antibacterial activity data of synthesized compounds (2a-2p, 3a-3p) is presented in Table 1. It very well may be seen from the table that every one of the mixtures have a recognizable level of restraint, particularly against B. pumilis, B. subtilis and E. coli. Compounds 2f, 2g, 2h, 2i, 2j, 2k, 2l, 2m, 2n, 2o, 2p, 3o and 3p just showed gentle inhibitory activity on P. vulgaris. Compounds 2g, 2h, 2j, 2k, 2l, 2m, 2n,2o, 2p, 3o and 3p have shown critical movement on *B. pumilis, B. subtilis, P. vulgaris* and *E. coli*. However, chloramphenicol is not having any activity against *B. pumilis*.

Table 1. Antibacterial activity of synthesized compounds (2a-2p, 3a-3p)

Compounds	Zone of inhibition (in mm)							
	B. pumilis		***B. subtilis***		***E. coli***		***P. vulgaris***	
	0.05 ml	**0.1 ml**	**0.05 ml**	**0.1 ml**	**0.05 ml**	**0.1 ml**	**0.05 ml**	**0.1 ml**
2a	8	9	6	7	6	7	-	-
2b	9	8	8	9	9	8	-	-
2c	7	9	8	10	8	9	-	-
2d	6	8	7	9	8	10	-	-
2e	8	10	7	8	7	9	-	-
2f	7	9	8	11	9	12	9	11
2g	12	15	13	15	12	16	12	16
2h	14	18	12	17	15	18	15	17
2i	8	10	10	14	13	16	11	13
2j	10	15	8	9	11	11	10	12
2k	11	12	9	11	7	10	8	11
2l	13	13	10	12	9	10	8	10
2m	11	13	10	13	10	12	9	11
2o	15	18	13	16	14	18	14	16
2p	11	15	11	15	10	12	9	12
3a	10	12	12	15	10	13	-	-
3b	8	11	9	10	11	11	-	-
3c	7	8	9	9	10	12	-	-
3d	9	10	8	9	7	9	-	-
3e	9	11	7	9	8	10	-	-
3f	8	10	8	10	8	11	-	-
3g	9	12	9	11	7	9	-	-
3h	7	10	8	10	9	12	-	-
3i	10	11	10	15	11	11	-	-
3j	8	9	10	10	8	11	-	-
3k	7	10	8	10	8	12	-	-
3l	8	9	7	10	9	11	-	-

Compounds	Zone of inhibition (in mm)							
	B. pumilis		***B. subtilis***		***E. coli***		***P. vulgaris***	
	0.05 ml	**0.1 ml**	**0.05 ml**	**0.1 ml**	**0.05 ml**	**0.1 ml**	**0.05 ml**	**0.1 ml**
3m	8	10	9	12	10	11	-	-
3o	13	15	14	15	15	18	12	14
3p	11	14	12	15	11	13	13	14
Chloramphenicol	-	-	17	-*	13	-*	12	-*

Concentration of the test compound: 100 pg/cup; Chloramphenicol: 200 pg/mL. (-) indicates no zone of inhibition; (-) indicates inhibition not done*

Anti-inflammatory activity: The anti-inflammatory activity of the sixteen chalcones (**2a-2p**) has been evaluated by using carrageenan-induced rat paw oedema method.

Calculation: It was calculated according to following formula,

$$\text{Percentage increase in paw thickness} = \frac{Yt - Yo}{Yo} \times 100$$

where Yt = paw thickness at the time 't' hours (After injection) Y0 = paw thickness at the time '0' hours (Before injection)

The percent increase in paw thickness during 6 hrs was determined. The percent inhibition ofpaw oedema thickness is calculated using the formula,

$$\text{Percentage inhibition} = \left[1 - \frac{Yt}{Yo}\right] \times 100$$

where Yt = Average increase in paw thickness in groups tested with test compounds Yc = Average increase in paw thickness in control.

The results of the evaluation have been viewed by taking Indomethacin as the standard drug. Compound **2o** has shown highest percent inhibition of 80.73 at 3rd hour. This has been followed by compounds **2p, 2g, 2k** and **2m** with highest percent inhibition of 78.35, 75.30, 69.83, and 65.59 respectively.

Table 2. Anti-inflammatory activity of synthesized compounds (2a-2p)

	Percent inhibition ± SEM at various time intervals				
Compound	**1 hr**	**2 hr**	**3 hr**	**4 hr**	**6 hr**
2a	48.36 ± 1.54	40.38±1.45	55.73 ± 5.34	54.43 ± 1.73	42.83 ± 5.83
2b	51.43± 1.45	45.47 ±1.48	58.31 ± 2.81	56.83 ± 2.93	44.73 ± 5.93
2c	59.67 ±1.69	50.54 ± 2.56	53.62 ± 5.75	60.84 ± 1.28	56.38 ± 5.28
2d	50.39 ± 1.48	52.43 ± 4.94	45.85 ± 4.83	41.83 ± 2.45	50.83 ± 5.84
2e	58.49 ± 2.28	60.83 ± 2.57	54.98 ± 2.91	51.93 ± 1.56	58.93 ± 2.90
2f	70.12 ± 5.65	71.43 ± 2.63	57.92 ± 4.01	69.73 ± 2.36	62.94 ± 5.47
2g	72.54 ± 1.98	75.76 ± 2.76	75.30 ± 5.57	70.83 ± 5.51	66.83 ± 5.38
2h	54.48 ± 2.48	56.76 ± 4.56	59.09 ± 2.83	65.83 ± 5.36	51.93 ± 2.57
2i	58.34 ± 2.40	61.59 ± 2.54	63.30 ± 2.91	60.63 ± 1.36	56.83 ± 2.62
2j	39.43 ± 2.65	51.43 ± 4.23	55.92 ± 5.77	50.83 ± 5.93	38.29 ± 1.27
2k	41.45± 2.74	66.83 ± 2.13	69.83 ± 2.92	65.93 ± 5.93	51.93 ± 2.95
2l	49.41 ± 5.54	55.73 ± 2.71	60.82 ± 2.28	58.93 ± 2.83	42.94 ± 2.49
2m	59.40 ± 2.10	51.32 ± 4.26	65.59 ± 2.93	62.93 ± 2.67	55.83 ± 5.72
2o	74.43 ± 2.65	78.52 ± 4.92	80.73 ± 5.83	75.83 ± 2.56	71.81 ± 2.16
2p	72.21 ± 5.56	77.83 ± 1.72	78.35 ± 5.16	75.72 ± 2.93	72.83 ± 1.38
Indomethacin	79.28 ± 4.94	85.45 ± 5.41	92.54 ± 2.74	81.45 ± 5.83	86.45 ± 5.83

***Dose:** Standard and sample solution is 100 mg/kg body weight. Values are expressed as mean ± SEM (n=6). *p< 0.05; ** p < 0.01; *** p < 0.001 compared to control. Student's t-test*

4. CONCLUSION

All the synthesized compounds (2a-2p, 3a-3p) have been evaluated for their antibacterial activity against, Bacillus pumilis, Bacillus subtilis (gram-positive) and Escherichia coli, Proteus vulgaris (gram-negative). It could be observed from the Table 1 that all the compounds have a noticeable

degree of inhibition, especially against *B. pumilis, B. subtilis* and *E. coli.* Compounds 2f, 2g, 2h, 2i, 2j, 2k, 2l, 2m, 2n, 2o, 2p, 3o and 3**p** only showed mild inhibitory action on *P. vulgaris.* Compounds 2g, 2h, 2j, 2k, 2l, 2m, 2n, 2o, 2p, 3o and 3p have shown significant activity on *B. pumilis, B. subtilis, P. vulgaris* and *E. coli.* It could be seen from the Table 1 that every one of the mixtures have a observable level of restraint, particularly against *B. pumilis, B. subtilis* and *E.coli*. Compounds 2f, 2g, 2h,2i,2j, 2k, 2l, 2m, 2n, 2o, 2p, 3o and 3p just showed gentle inhibitory activity on P.vulgaris. Compounds 2g, 2h, 2j, 2k, 2l, 2m, 2n, 2o, 2p, 3o and 3p have shown huge action on *B. pumilis, B. subtilis, P. vulgaris* and *E. coli*. It is tooseen from the Table 1 that every one of the mixtures displayed impressive inhibitory activity uniquely against A.

Niger and R. oryzae. Be that as it may, their activity has been viewed as extremely feeble against A. flavus. Compounds 2m, 2o,2p,3i and 3p have shown high intensity uniquely against A. niger, R. oryzae furthermore A. flavus. The mitigating action of the sixteen chalcones (2a-2p) has been assessed by utilizing carrageenan-incited rodent paw oedema strategy (Table 2 and Fig. 1). Compound 2o has shown most noteworthy percent hindrance of 80.73 at 3. This has been trailed by compounds 2p, 2g, 2k and 2m with most noteworthy percent inhibition of 78.35, 75.30, 69.83, and 65.59 individually.



Fig. 1. Anti-inflammatory activity of synthesized compounds (2a-2p)

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ni L, Meng CQ, Sikorski JA. Recent advances in therapeutic chalcones. Expert Opin. Ther. Pat. 2004;14:1669-1691.
2. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. European Journal of Medicinal Chemistry. 2007;42:125-137.
3. Dimmock JR, Elias DW, Beazely MA, Kandepu NM. Bioactivities of chalcones. Curr. Med. Chem. 1999;6:1125-1149. Dziedzic SZ, Hudson BJF. Polyhydroxy chalcones and flavanones as antioxidants for edible oils. Food Chemistry. 1983;12(3):205-212.
4. Furniss BS, Hannaford AJ, Rogers V, Smith PWG, Tatchell AR. Vogel's Textbook of Practical Organic Chemistry, 5th ed.; Longman Group Limited: New York, p. 1034. Ganesh A. Biological activities of some pyrazoline derivatives Int J Pharm Bio Sci. 1989;4(2):727-733.
5. Kumar R, Mohanakrishnan D, Sharma A, Kaushik NK, Kalia K, Sinha AK, Sahal D. Reinvestigation of structure-activity relationship of methoxylated chalcones as

antimalarials: Synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural α-asarone. European Journal of Medicinal Chemistry. 2010;45:5292-5301

6. Sonmez F, Sevmezler S, Atahan A, Ceylan M, Demir D, Gencer N, Arslan O, Kucukislamoglu M. Evaluation of new chalcone derivatives as polyphenol oxidase inhibitors. Bioorg. Med. Chem. Lett. 2011;21:7479-7482.
7. Leon C, Rodrigues J, Dominguez N, Rosenthal PJ, Dominguez JN. Synthesis and evaluation of sulfonylurea derivatives as novel antimalarials. Eur. J. Med. Chem. 2007;42:735-742.
8. Ozdemir A, Turan-Zitouni G, Kaplancikli ZM. Novel analogues of 2-pyrazoline: Synthesis and antimycobacterial evaluation. Turk. J. Chem. 2008;32:529-538.
9. Kini S, Gandhi AM. Novel 2-pyrazoline derivatives as potential antibacterial and antifungal agents. Indian J. Pharm. Sci. 2008;70:105-108.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/82932